Biotech | February 28, 2022
BDR Pharma launches enzalutamide in 160 mg strength
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
Clinical trial supply company strengthens its presence in the European Union
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Subscribe To Our Newsletter & Stay Updated
